Abstract:Metabolic dysfunction-associated fatty liver disease (MAFLD) has a global prevalence of about 25% and no approved therapy. Using metabolomic and proteomic analyses, we identified high expression of hepatic transketolase (TKT), a metabolic enzyme of the pentose phosphate pathway, in human and mouse MAFLD. Hyperinsulinemia promoted TKT expression through the insulin receptor-CCAAT/enhancer-binding protein alpha axis. Utilizing liver-specific TKT overexpression and knockout mouse models, we demonstrated that TKT was sufficient and required for MAFLD progression. Further metabolic flux analysis revealed that Tkt deletion increased hepatic inosine levels to activate the protein kinase A-cAMP response element binding protein cascade, promote phosphatidylcholine synthesis, and improve mitochondrial function. Moreover, insulin induced hepatic TKT to limit inosine-dependent mitochondrial activity. Importantly, N-acetylgalactosamine (GalNAc)-siRNA conjugates targeting hepatic TKT showed promising therapeutic effects on mouse MAFLD. Our study uncovers how hyperinsulinemia regulates TKT-orchestrated inosine metabolism and mitochondrial function and provides a novel therapeutic strategy for MAFLD prevention and treatment.

What problem does this paper attempt to address?

This paper attempts to address the pathogenesis of metabolic - dysfunction - associated fatty liver disease (MAFLD), especially to explore the role of transketolase (TKT) in this process. Specifically, the study focuses on the following aspects: 1. **TKT expression induced by hyperinsulinemia**: Studies have shown that hyperinsulinemia activates TKT transcription through the insulin receptor - CCAAT/enhancer - binding protein α (Insr - CEBPα) pathway, thereby limiting mitochondrial function. 2. **The impact of TKT on inosine metabolism**: The up - regulation of TKT promotes the catabolism of inosine in the liver, interferes with the inosine - PKA - CREB - phosphatidylcholine (PC) cascade reaction, and further affects mitochondrial function. 3. **GalNAc - siRNA - targeted treatment strategy**: The study found that using GalNAc - siRNA to target and inhibit TKT expression in the liver can significantly improve steatohepatitis and fibrosis, providing a potential treatment strategy for MAFLD. ### Main conclusions - **The key role of TKT in MAFLD**: Studies have proven that over - expression of TKT can promote the development of MAFLD, while its knockout can alleviate the symptoms of MAFLD. - **Mechanism analysis**: Hyperinsulinemia up - regulates the expression of TKT through the Insr - CEBPα pathway, thereby limiting mitochondrial activity. In addition, the lack of TKT leads to the accumulation of inosine and enhances mitochondrial function by activating the PKA - CREB - PC axis. - **Treatment potential**: GalNAc - siRNA - targeted inhibition of TKT expression has shown significant therapeutic effects in mouse models, suggesting that it may become an effective treatment method for MAFLD. ### Formulas and mechanisms 1. **Insulin signaling pathway**: \[ \text{Insulin} \rightarrow \text{Insr} \rightarrow \text{p - CEBP}\alpha \rightarrow \text{TKT} \] Insulin activates the insulin receptor (Insr), further phosphorylates CEBPα, and thus up - regulates the expression of TKT. 2. **Inosine metabolism pathway**: \[ \text{Glucose} \xrightarrow{\text{PPP}} \text{R5P} \xrightarrow{\text{TKT}} \text{Gly3P, Sed7P} \quad \text{(Under normal conditions)} \] \[ \text{Glucose} \xrightarrow{\text{PPP}} \text{R5P} \rightarrow \text{Inosine} \quad \text{(When TKT is absent)} \] In the absence of TKT, R5P generated from glucose through PPP cannot effectively enter glycolysis but is more used for inosine synthesis. 3. **PKA - CREB - PC axis**: \[ \text{Inosine} \rightarrow \text{cAMP} \rightarrow \text{PKA} \rightarrow \text{CREB} \rightarrow \text{PC synthesis} \] Inosine activates the cAMP - PKA pathway, further activates CREB, and promotes PC synthesis, thereby improving mitochondrial function. In summary, this study reveals how hyperinsulinemia affects inosine metabolism and mitochondrial function by regulating TKT expression and proposes a new strategy for treating MAFLD.

Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity

Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis

Targeting Intestinal Transporter Glut5 to Prevent the High Fructose-Induced Steatotic Liver Disease

Characterization of an In Vitro Steatosis Model Simulating Activated De Novo Lipogenesis in MAFLD Patients

Mechanisms and therapeutic strategies for MAFLD targeting TLR4 signaling pathways

Transketolase Deficiency in Adipose Tissues Protects Mice From Diet-Induced Obesity by Promoting Lipolysis

Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice

Acetylation of Mitochondrial Trifunctional Protein α-Subunit Enhances Its Stability To Promote Fatty Acid Oxidation and Is Decreased in Nonalcoholic Fatty Liver Disease

Liver knockout of MCU leads to greater dysregulation of lipid metabolism in MAFLD

Mtfp1 ablation enhances mitochondrial respiration and protects against hepatic steatosis

Longitudinal Analysis of Mitochondrial Function in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis Mouse Model

Transketolase drives the development of aortic dissection by impairing mitochondrial bioenergetics

Repurposing of the analgesic Neurotropin for MASLD/MASH treatment

Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease

[METTL3 inhibitor STM2457 improves metabolic dysfunction-associated fatty liver disease by regulating mitochondrial function in mice]

Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD

Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice

METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression

Anterograde regulation of mitochondrial genes and FGF21 signaling by hepatic LSD1

Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease

MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites